Partially Randomized, Non-Blinded Trial of DNA and MVA Therapeutic Vaccines Based on Hepatitis B Virus Surface Protein for Chronic HBV Infection Therapy
2011

Therapeutic Vaccines for Chronic Hepatitis B Infection

Sample size: 72 publication Evidence: low

Author Information

Author(s): Cavenaugh James S., Awi Dorka, Mendy Maimuna, Hill Adrian V. S., Whittle Hilton, McConkey Samuel J.

Primary Institution: Medical Research Council Laboratories, Banjul, The Gambia

Hypothesis

Can a combination of DNA and MVA vaccines effectively treat chronic HBV infection?

Conclusion

The vaccines were well tolerated but did not control HBV infection.

Supporting Evidence

  • The vaccines were well tolerated with mild adverse events.
  • One participant lost HBeAg, but no significant changes in viral load were observed.
  • Lamivudine therapy reduced viral load, but the vaccine regimen did not.

Takeaway

The study tested new vaccines to help people with chronic hepatitis B, but they didn't work as hoped.

Methodology

Participants were randomly assigned to receive different vaccine regimens or lamivudine therapy, and their immune responses and safety were monitored.

Potential Biases

No significant bias risks were reported, but the lack of blinding could introduce some bias.

Limitations

The study was not blinded, and the sample size may not have been large enough to detect small effects.

Participant Demographics

Healthy males aged 15-25 with chronic HBV infection.

Digital Object Identifier (DOI)

10.1371/journal.pone.0014626

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication